The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, activecontrolled, double-blind trial
Publication: The Lancet
Comparing population level humoral and cellular immunity to SARS Cov 2 in Bangalore- India
Publication: Scientific Reports
Syngene’s Center of Excellence for Oligonucleotides: Early Discovery to cGMP manufacturing services
Our Oligonucleotides facility offers end-to-end services, from early discovery to cGMP manufacturing. Specialty areas include chemically synthesized high-quality modified and non-modified custom oligonucleotide (DNA/RNA); siRNA (single & double-stranded); miRNA (modified and non-modified); antisense oligonucleotides; phosphodiesters and morpholinos; all types of oligo conjugates, and all types of base and custom modifications.
Syngene’s Small Molecule cGMP commercial manufacturing facility
Syngene’s state-of-the-art small molecule cGMP manufacturing facility is USFDA and PMDA-approved. The facility manufactures clinical (early and late-phase) and commercial drug substances (NCEs), advanced intermediates, regulatory starting materials, and selected generic APIs for clients. The facility’s manufacturing output ranges from grams to hundreds of kilograms per batch, with total volumes ranging from 60L to 8000L.
Syngene’s high potent API manufacturing facility
Our high potent API facility is designed to handle cytotoxic and cytostatic high-potency compounds with a commitment to safety.
How Syngene supported a large pharma company in generating gene knockouts in iPSCs with >95% efficiency
Learn how Syngene helped generate human iPSCs gene knockouts with >95% efficiency for an allogeneic cell and gene therapy.
Cracking the Code: Transformative role of pDNA in advanced modalities
Reasons behind the rise in demand for pDNA and what to look for in a pDNA engineering and manufacturing partner when deciding to outsource.
Pharma Supply Chain: From Fragile to Agile
CDMOs bolster supply networks with additional capabilities to make themselves resilient to potential challenges and ensure secure supplies to customers.
Quality management paradigm shift: Risk-centric practices come center stage
CDMOs have moved to risk-based quality management systems comprising highly integrated and digitalized processes powered by data to ensure drug quality.
Protein therapeutics to amp up outsourcing in animal health
With the boom in pet ownership and rising awareness about pet health, veterinary drug makers are betting big on protein therapeutics and outsourcing biologics development to CDMOs.